Biotechnology

BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025

May 14, 2025 9:45 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that additional data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in Cutaneous T-cell Lymphoma (CTCL) will be presented in a poster at the European Hematology Association (EHA) 2025 congress to take...

Read more

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

May 14, 2025 9:40 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces latest updated data from the ongoing Phase 2a study of BI-1206 in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL). Additionally today, an abstract containing data...

Read more

Faron Pharmaceuticals Ltd: Grant of Options

May 14, 2025 9:25 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN): Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, todayannounces that the Company's board has confirmed the grant of a total of 876,000options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019 (including its UK and US sub plans). The Options have been...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 8:05 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2025. Recent Highlights Announced that its collaboration partner, PeriNess Ltd., entered into a Clinical Study Agreement to advance development of DNase platform for the treatment of...

Read more

ClearPoint Neuro Reports First Quarter 2025 Results

May 13, 2025 4:40 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2025. First Quarter Highlights Reported record quarterly revenue of $8.5 million, an 11% year-over-year increase compared with the first quarter of 2024; Grew total consumable product revenue by $2.6 million...

Read more

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13, 2025 8:45 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, "Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux1," has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the...

Read more

Gator Bio Unveils Novel New GeneSwift Reagents Revolutionizing Genome Titer and Genome Integrity Analysis

May 13, 2025 8:00 AM

Gator Bio, a leader in innovative biotechnology solutions, proudly announced availability of its latest breakthrough: the GeneSwift reagents. These cutting-edge kits redefine genome titer and integrity determination, delivering unmatched speed, simplicity, and precision compared to traditional ddPCR-based assays, which require significant expertise and long run times. By eliminating the need for outsourcing to specialized labs, which can delay...

Read more

Peer-Reviewed Study Validates Microarray Platform for Tickborne and Vector-Borne Infections

May 13, 2025 7:45 AM

A new study published in Nature Scientific Reports validates the performance of a customizable multiplex protein microarray developed by Vibrant Sciences, the research arm of lab testing company Vibrant Wellness. The peer-reviewed findings confirm that the platform enables highly sensitive, simultaneous antibody detection for over 17 tickborne and related pathogens, offering a faster, more comprehensive approach to infectious disease testing....

Read more

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 6:00 AM

AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a collaboration with Single Cell Technology and Vaccinex. AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb® Technology into their respective workflows for complex drug targets. AbTherx's antibody discovery platform is built on two decades of experience and utilizes evolutionary...

Read more

Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa

May 13, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer Biovica's blood-based treatment monitoring test, DiviTum TKa, as part of its comprehensive portfolio of diagnostics for oncologists. Through the collaboration, Biovica and Tempus will work together to commercialize...

Read more

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

May 12, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal quarter that ended March 31, 2025, as well as the launch of the purpose-built subsidiary, NCTx. Michael Heltzen, CEO of eXoZymes, states, "We have reached our first commercial milestone by...

Read more

ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing

May 12, 2025 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital...

Read more

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025 9:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's...

Read more

Longwood Fund Strengthens Growth-Stage Investment Team

May 12, 2025 7:00 AM

Longwood Fund, a venture capital firm creating and investing in science-based companies that develop important treatments to help patients, today announced that it has further strengthened its investment team with the promotion of Vikas Goyal, MBA, to Partner, focusing on growth stage investments in late preclinical and clinical stage biotechnology companies. Mr. Goyal has more than 20 years of experience as both a venture investor and executive...

Read more

Moolec Science Announces Effectiveness of Reverse Stock Split

May 12, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC; the "Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on April 22, 2025, and the resolutions adopted by the Company's board of directors on the same date, the Company has approved a reverse stock split at a...

Read more

AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration

May 12, 2025 6:00 AM

AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a multi-program antibody discovery partnership with Spice Biotechnologies. The partnership will leverage AbTherx's suite of innovative Atlas™ Mouse technologies to deliver antibodies against targets selected by Spice Bio. AbTherx's antibody discovery platform is built on two decades of experience and...

Read more

Alligator Bioscience to Attend ASCO 2025 Annual Meeting

May 12, 2025 2:50 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) is pleased to announce that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, titled "Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer," will take place during the Developmental...

Read more

Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session

May 12, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDS Encouraging survival; Median overall survival 13.4 months in 20 high and very high-risk r/r MDS patients treated with bexmarilimab + azacitidine; 4 patients successfully bridged to hematopoietic stem cell transplant 55% patients showed ≥50% reduction in bone marrow; 21% of...

Read more

Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025

May 9, 2025 1:00 PM

Jabez Biosciences, Inc., a pioneering biotechnology company focused on innovative cancer therapies, proudly shared the progress of its Phase 1 clinical trial for JBZ-001 (HOSU-53), a novel dihydroorotate dehydrogenase (DHODH) inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting held April 25-30, 2025, in Chicago, IL. The trial, conducted in collaboration with The Ohio State University Comprehensive Cancer...

Read more

Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

May 9, 2025 10:15 AM

Alligator Bioscience (STO:ATORX)("Alligator Bioscience" or the "Company") hereby announces that the Company has received undertakings corresponding to 85 per cent of the outstanding warrants series TO 12 ("TO 12") (the "Warrant Programme"). The Company has received subscription undertakings from the Company's Chairman of the Board of Directors, CEO and CFO as well as several larger and smaller holders of TO 12, including Roxette Photo SA,...

Read more